GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
-2.74%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$202M
AUM Growth
+$202M
(-23%)
Cap. Flow
-$25.9M
Cap. Flow
% of AUM
-12.83%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
52
New
5
Increased
8
Reduced
20
Closed
9
Top Buys
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$7.61M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$5.69M |
| 3 |
Amicus Therapeutics
FOLD
|
$5.68M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$4.39M |
| 5 |
Axsome Therapeutics
AXSM
|
$3.91M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$5.87M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$5.09M |
| 3 |
CMPS
Compass Pathways
CMPS
|
$4.64M |
| 4 |
Sarepta Therapeutics
SRPT
|
$3.91M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$3.81M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $16.4M | 3.57% | 140,000 -50,000 | -26% | -$5.87M |
|
2
Cogent Biosciences
COGT
$1.69B
| $12.7M | 2.76% | 1,700,000 | – | – |
|
|
3
Apellis Pharmaceuticals
APLS
$3.48B
| $12.7M | 2.76% | 250,000 -75,000 | -23% | -$3.81M |
|
4
Merus
MRUS
$4.98B
| $10.6M | 2.3% | 400,000 +50,000 | +14% | +$1.32M |
|
|
5
Amicus Therapeutics
FOLD
$2.34B
| $10.4M | 2.26% | 1,100,000 +600,000 | +120% | +$5.68M |
|
|
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.4M | 2.26% | 325,000 +75,000 | +30% | +$2.4M |
|
7
Celldex Therapeutics
CLDX
$1.47B
| $10.2M | 2.22% | 300,000 -50,000 | -14% | -$1.7M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $8.62M | 1.87% | 466,403 -33,597 | -7% | -$621K |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.61M | 1.65% | +60,000 | New | +$7.61M |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.57M | 1.64% | 450,000 -175,000 | -28% | -$2.95M |
|
11
Arvinas
ARVN
$568M
| $7.4M | 1.61% | 110,000 | – | – |
|
12
Vaxcyte
PCVX
$4B
| $7.25M | 1.57% | 300,000 +50,000 | +20% | +$1.21M |
|
13
Kezar Life Sciences
KZR
$28.9M
| $6.65M | 1.44% | 400,000 +150,000 | +60% | +$2.49M |
|
|
CTIC
14
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $6.07M | 1.32% | 1,300,000 +100,000 | +8% | +$467K |
|
|
15
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.69M | 1.24% | +350,000 | New | +$5.69M |
|
16
RAPT Therapeutics
RAPT
$188M
| $5.5M | 1.19% | 250,000 -100,000 | -29% | -$2.2M |
|
|
BCYC
17
Bicycle Therapeutics
BCYC
$511M
| $4.39M | 0.95% | +100,000 | New | +$4.39M |
|
|
18
Axsome Therapeutics
AXSM
$6.05B
| $3.91M | 0.85% | +94,500 | New | +$3.91M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $3.91M | 0.85% | 225,000 -75,000 | -25% | -$1.3M |
|
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $3.91M | 0.85% | 50,000 -50,000 | -50% | -$3.91M |
|
|
VRNA
21
Verona Pharma
VRNA
$9.16B
| $3.74M | 0.81% | 750,000 | – | – |
|
22
Zentalis Pharmaceuticals
ZNTL
$122M
| $3.69M | 0.8% | 80,000 | – | – |
|
23
Design Therapeutics
DSGN
$315M
| $3.23M | 0.7% | 200,000 +65,000 | +48% | +$1.05M |
|
24
Rocket Pharmaceuticals
RCKT
$354M
| $3.17M | 0.69% | 200,000 -225,000 | -53% | -$3.57M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $3.06M | 0.66% | 100,000 | – | – |
|